公开(公告)号：US20180327809A1

公开(公告)日：2018-11-15

申请号：US15839387

申请日：2017-12-12

Applicant: Concert Pharmaceuticals, Inc.

Inventor： Roger Tung

IPC: C12Q1/28 ,  G01N33/493 ,  G01N33/49 ,  A61K31/49 ,  A61K31/195 ,  C07B59/00 ,  C07D471/08 ,  A61K31/485 ,  A61K31/4709 ,  C07D221/28

CPC classification number: C12Q1/28 ,  A61K31/195 ,  A61K31/4709 ,  A61K31/485 ,  A61K31/49 ,  C07B59/002 ,  C07D221/28 ,  C07D471/08 ,  G01N33/491 ,  G01N33/493

Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σi receptor agonist that also has NMDA antagonist activity.

公开(公告)号：US09072711B2

公开(公告)日：2015-07-07

申请号：US14141694

申请日：2013-12-27

Applicant: Concert Pharmaceuticals, Inc.

Inventor： Roger Tung

IPC: A61K31/4748 ,  A61K31/195 ,  C07B59/00 ,  A61K31/4709 ,  A61K31/485 ,  C07D221/28 ,  C07D471/08 ,  A61K31/49

CPC classification number: A61K31/195 ,  A61K31/4709 ,  A61K31/485 ,  A61K31/49 ,  C07B59/002 ,  C07D221/28 ,  C07D471/08

Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

Abstract translation: 本公开涉及新的吗啡喃化合物及其衍生物，其药学上可接受的盐，溶剂合物和水合物。 本公开还提供了包含本公开的化合物的组合物以及这些组合物在治疗通过施用也具有NMDA拮抗剂活性的1受体激动剂有益治疗的疾病和病症的方法中的用途。

公开(公告)号：US20150299170A1

公开(公告)日：2015-10-22

申请号：US14646695

申请日：2013-11-20

Applicant: CONCERT PHARMACEUTICALS, INC.

Inventor： Bhaumik A. Pandya ,  Roger Tung

IPC: C07D401/14 ,  A61K45/06 ,  C07B59/00 ,  A61K31/4545

CPC classification number: C07D401/14 ,  A61K31/44 ,  A61K31/4545 ,  A61K31/517 ,  A61K45/06 ,  C07B59/002 ,  C07B2200/05 ,  A61K2300/00

Abstract: This invention relates to novel fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).

Abstract translation: 本发明涉及式I的吡唑取代的氨基 - 杂芳基化合物的新的氟衍生物及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这种组合物在治疗通过施用间变性淋巴瘤激酶（ALK）的抑制剂有益治疗的疾病和病症的方法中的用途。

公开(公告)号：US09145390B2

公开(公告)日：2015-09-29

申请号：US14016791

申请日：2013-09-03

Applicant: CoNCERT Pharmaceuticals, Inc.

Inventor： Bhaumik Pandya ,  Craig E. Masse ,  Ian Robert Silverman ,  Roger Tung

IPC: C07D401/14 ,  A61K31/4545 ,  A61K45/06 ,  A61K31/44 ,  A61K31/517

CPC classification number: A61K31/4545 ,  A61K31/44 ,  A61K31/517 ,  A61K45/06 ,  C07D401/14 ,  A61K2300/00

Abstract: This invention relates to novel pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).

Abstract translation: 本发明涉及式I的新型吡唑取代的氨基 - 杂芳基化合物及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这种组合物在治疗通过施用间变性淋巴瘤激酶（ALK）的抑制剂有益治疗的疾病和病症的方法中的用途。

公开(公告)号：US20140155444A1

公开(公告)日：2014-06-05

申请号：US14059068

申请日：2013-10-21

Applicant: Concert Pharmaceuticals Inc.

Inventor： Roger Tung ,  Craig E. Masse ,  Bhaumik A. Pandya

IPC: C07D235/16 ,  A61K45/06 ,  A61K31/4184

CPC classification number: C07D235/16 ,  A61K31/4184 ,  A61K45/06 ,  C07D235/14

Abstract: This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment: as described herein. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a selective T-type calcium channel blocker.

Abstract translation: 本发明涉及新的四氢萘衍生物及其药学上可接受的盐，在一个实施方案中：如本文所述。 本发明还提供包含本发明化合物的组合物和这些组合物在治疗通过施用选择性T型钙通道阻断剂有益治疗的疾病和病症的方法中的用途。

公开(公告)号：US20140113925A1

公开(公告)日：2014-04-24

申请号：US14141694

申请日：2013-12-27

Applicant: Concert Pharmaceuticals, Inc.

Inventor： Roger Tung

IPC: C07D221/28 ,  A61K31/485 ,  A61K31/195 ,  A61K31/4709

CPC classification number: A61K31/195 ,  A61K31/4709 ,  A61K31/485 ,  A61K31/49 ,  C07B59/002 ,  C07D221/28 ,  C07D471/08

Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

Abstract translation: 本公开涉及新的吗啡喃化合物及其衍生物，其药学上可接受的盐，溶剂合物和水合物。 本公开还提供了包含本公开的化合物的组合物以及这些组合物在治疗通过施用也具有NMDA拮抗剂活性的1受体激动剂有益治疗的疾病和病症的方法中的用途。

公开(公告)号：US20130310415A1

公开(公告)日：2013-11-21

申请号：US13949499

申请日：2013-07-24

Applicant: Concert Pharmaceuticals Inc.

Inventor： Roger Tung

IPC: A61K31/485 ,  A61K31/4709 ,  C07D221/28

CPC classification number: A61K31/195 ,  A61K31/4709 ,  A61K31/485 ,  A61K31/49 ,  C07B59/002 ,  C07D221/28 ,  C07D471/08

Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

Abstract translation: 本公开涉及新的吗啡喃化合物及其衍生物，其药学上可接受的盐，溶剂合物和水合物。 本公开还提供了包含本公开的化合物的组合物以及该组合物在治疗通过施用也具有NMDA拮抗剂活性的σ1受体激动剂有益治疗的疾病和病症的方法中的用途。

公开(公告)号：US08993570B2

公开(公告)日：2015-03-31

申请号：US13959716

申请日：2013-08-05

Applicant: Concert Pharmaceuticals, Inc.

Inventor： Scott L. Harbeson ,  Roger Tung ,  Julie F. Liu

IPC: A01N43/58 ,  A61K31/495 ,  C07D487/00 ,  A61K31/5025 ,  A61K45/06 ,  C07D487/04

CPC classification number: C07D487/04 ,  A61K31/5025 ,  A61K45/06

Abstract: This invention relates to novel substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α1-GABAA receptor antagonist or an α2- and/or an α3-GABAA receptor partial agonist.

Abstract translation: 本发明涉及新的取代三唑并 - 哒嗪及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这些组合物在治疗通过施用α1-GABA A受体拮抗剂或α2-和/或α3-GABA A受体部分激动剂有益治疗的疾病和病症的方法中的用途 。

公开(公告)号：US20240117407A1

公开(公告)日：2024-04-11

申请号：US18306710

申请日：2023-04-25

Applicant: Concert Pharmaceuticals, Inc.

Inventor： Roger Tung

IPC: C12Q1/28 ,  A61K31/195 ,  A61K31/4709 ,  A61K31/485 ,  A61K31/49 ,  C07B59/00 ,  C07D221/28 ,  C07D471/08 ,  G01N33/49 ,  G01N33/493

CPC classification number: C12Q1/28 ,  A61K31/195 ,  A61K31/4709 ,  A61K31/485 ,  A61K31/49 ,  C07B59/002 ,  C07D221/28 ,  C07D471/08 ,  G01N33/491 ,  G01N33/493

Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

公开(公告)号：US20210348208A1

公开(公告)日：2021-11-11

申请号：US17120880

申请日：2020-12-14

Applicant: Concert Pharmaceuticals, Inc.

Inventor： Roger Tung

IPC: C12Q1/28 ,  C07B59/00 ,  C07D471/08 ,  A61K31/195 ,  A61K31/4709 ,  A61K31/485 ,  A61K31/49 ,  C07D221/28 ,  G01N33/49 ,  G01N33/493

Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a al receptor agonist that also has NMDA antagonist activity.